Initial low-density lipoprotein response to statin therapy predicts subsequent low-density lipoprotein response to the addition of ezetimibe - 26/08/11
Doi : 10.1016/j.amjcard.2003.11.060
Paul E. Ziajka, MD, PhD a, ⁎ 
, Mary Reis, MS b, Sandra Kreul, MSN c, Helen King, RN d
, Mary Reis, MS b, Sandra Kreul, MSN c, Helen King, RN d a The Florida Lipid Institute, Orlando, Florida, USA
b Heart and Vascular Institute of Florida, Safety Harbor, Florida, USA
c Benedict Maniscalco, MD, PA, Tampa, Florida, USA
d Heart and Vascular Institute of Florida, Saint Petersburg, Florida, USA
*Dr. Ziajka's address is: 1511-B Sligh Boulevard, Orlando, Florida 32806, USA.
Abstract |
This small retrospective study confirms the hypothesis that patients who are hyporesponders to statin therapy are hyper-responders to ezetimibe therapy and may help identify a patient population in whom ezetimibe would be particularly effective in lowering low-density lipoprotein cholesterol.
Il testo completo di questo articolo è disponibile in PDF.© 2004
Excerpta Medica Inc. Tutti i diritti riservati.
Vol 93 - N° 6
P. 779-780 - marzo 2004 Ritorno al numero
Articolo precedente
- Superior short-term cholesterol control and achievement of the adult treatment panel III low-density lipoprotein goals with initiation of statin therapy by the time of hospital discharge following acute myocardial infarction
- Kevin A. Bybee, Brian D. Powell, Brent A. Williams, Joseph G. Murphy, Stephen L. Kopecky, R.Scott Wright
- Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion
- Arnljot Tveit, Morten Grundtvig, Torstein Gundersen, Paul Vanberg, Anne Grete Semb, Even Holt, Lars Gullestad
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?